UPDATE: COVID-19 Read the Message

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Apr 15, 2021
- Evrysdi increased survival and reduced need for permanent ventilation - SOUTH PLAINFIELD, N.J. , April 15, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular
Additional Formats
Apr 14, 2021
- Provides easier access to genetic testing for patients with symptoms or diagnosis of cerebral palsy at no charge - SOUTH PLAINFIELD, N.J. , April 14, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United
Additional Formats
Apr 07, 2021
SOUTH PLAINFIELD, N.J. , April 7, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Don Clifton Strengths-Based Culture Award" from Gallup. The award recognizes organizations with strong workplace cultures that get the best out
Additional Formats
Apr 07, 2021
SOUTH PLAINFIELD, N.J. , April 7, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T. The Huntington Disease Deep Dive will provide an overview of PTC's
Additional Formats
Apr 01, 2021
SOUTH PLAINFIELD, N.J. , April 1, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi ™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche.
Additional Formats
Mar 30, 2021
- First and only at home treatment approved for SMA - - Proven efficacy in adults and children with SMA 2 months and older - SOUTH PLAINFIELD, N.J. , March 30, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the European Commission (EC) has granted marketing
Additional Formats
Mar 16, 2021
- Sustained or improved motor function was observed with 24 months of treatment - - Patients and caregivers reported a greater ability to complete activities of daily livingwith increased independence - SOUTH PLAINFIELD, N.J. , March 16, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT)
Additional Formats
Mar 15, 2021
- Desire to slow disease progression and tolerability issues were the primary reasons for switching from prednisone to EMFLAZA® (deflazacort) - - Delayed disease progression and improved benefit-risk reported during the 6-month average follow up after switching to EMFLAZA - SOUTH PLAINFIELD, N.J.
Additional Formats
Mar 09, 2021
-SMA Foundation and PTC Therapeutics to commit to an initial investment of up to $60 million in research to discover and develop promising regenerative treatments in neuromuscular diseases- NEW YORK and SOUTH PLAINFIELD, N.J. , March 9, 2021 /PRNewswire/ -- The Spinal Muscular Atrophy (SMA)
Additional Formats
Feb 26, 2021
- Evrysdi is the first and only at-home treatment for SMA patients - - Opinion based on efficacy results from the FIREFISH and SUNFISH pivotal trials - SOUTH PLAINFIELD, N.J. , Feb. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency
Additional Formats